Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Controlled antibody delivery systems.

J K Sherwood1, R B Dause, W M Saltzman

  • 1Department of Chemical Engineering, Johns Hopkins University, Baltimore, MD 21218.

Bio/Technology (Nature Publishing Company)
|November 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors.

Molecular cancer therapeutics·2024
Same author

Monobody adapter for functional antibody display on nanoparticles for adaptable targeted delivery applications.

Nature communications·2022
Same author

Nerve growth factor delivery and cell aggregation enhance choline acetyltransferase activity after neural transplantation.

Tissue engineering·2009
Same author

Initial evaluation of the use of USPIO cell labeling and noninvasive MR monitoring of human tissue-engineered vascular grafts in vivo.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2008
Same author

Small-diameter biodegradable scaffolds for functional vascular tissue engineering in the mouse model.

Biomaterials·2008
Same author

Nonviral gene delivery: thinking of silica.

Gene therapy·2007
Same journal

Molecular Farming: Transgenic Animals as Bioreactors.

Bio/technology (Nature Publishing Company)·2020
Same journal

Development of a Genetically-Engineered, Candidate Polio Vaccine Employing the Self-Assembling Properties of the Tobacco Mosaic Virus Coat Protein.

Bio/technology (Nature Publishing Company)·2020
Same journal

FDA User Fees Gain Momentum.

Bio/technology (Nature Publishing Company)·2020
Same journal

Cloning of a Gene Involved in Antibiotic Synthesis.

Bio/technology (Nature Publishing Company)·2020
Same journal

The Biology of the Interferon System.

Bio/technology (Nature Publishing Company)·2020
Same journal

Development of new cloning vectors for the production of immunogenic outer membrane fusion proteins in Escherichia coli.

Bio/technology (Nature Publishing Company)·1996
See all related articles

Researchers developed polymer systems for controlled antibody release. These biocompatible and biodegradable drug delivery systems show potential for therapeutic antibody applications.

Area of Science:

  • Biomaterials Science
  • Polymer Chemistry
  • Immunology

Background:

  • Controlled drug delivery systems are crucial for therapeutic applications.
  • Biocompatible and biodegradable polymers offer versatile platforms for drug encapsulation and release.
  • Antibody-based therapies require stable and effective delivery methods.

Purpose of the Study:

  • To develop and evaluate biocompatible and biodegradable polymer matrices for controlled antibody release.
  • To assess the stability and functionality of antibodies after release from polymeric carriers.
  • To explore the potential of these systems for in vivo therapeutic applications.

Main Methods:

  • Incorporation of human antibodies, antibody fragments, and mouse monoclonal antibodies (mAbs) into poly(ethylene-co-vinyl acetate) (EVAc) and poly-anhydride copolymer matrices.

Related Experiment Videos

  • Evaluation of antibody release profiles over 30 days of immersion in buffered saline.
  • Assessment of antibody functionality (antigen binding) and aggregation post-release.

    • Main Results:

    • Slow and sustained release of antibodies from both EVAc and biodegradable poly-anhydride matrices over 30 days.
    • Retained antigen-binding capacity of anti-hCG antibodies released from EVAc matrices.
    • Minimal antibody aggregation observed after release from both types of polymeric carriers.

    Conclusions:

    • Polymer-based systems can effectively control the release of antibodies.
    • Released antibodies maintain their biological activity and structural integrity.
    • These polymeric delivery systems hold promise for future antibody-based immunoprotection and immunotherapy applications.